1319591-26-8

Basic information

• Product Name: 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-1H-pyrazolo[3,4-b]pyridine
• Synonyms: 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-1H-pyrazolo[3,4-b]pyridine
• CAS NO: 1319591-26-8
• Molecular Weight: 487.409
• Mol File: 1319591-26-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-1H-pyrazolo[3,4-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-1H-pyrazolo[3,4-b]pyridine(1319591-26-8)
• EPA Substance Registry System: 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-1H-pyrazolo[3,4-b]pyridine(1319591-26-8)

Safety Data

• Hazardous Substances Data: 1319591-26-8(Hazardous Substances Data)

Usage

Chemical compound type

Boron-containing pyrazolopyridine
Use in organic synthesis and medicinal chemistry as a building block

Structure

Boron atom coordinated to a dioxaborolane ring attached to a trityl-protected pyrazolopyridine
Trityl group used as a protecting group in organic synthesis for reaction selectivity
Versatile intermediate for pharmaceuticals, agrochemicals, and advanced materials

Upstream product

• 36404-88-3 2-chloro-3-carbaldehydepyridine 
• 1383446-28-3 3-bromo-1-trityl-pyrazolo[3,4-b]pyridine 
• 73183-34-3 bis(pinacol)diborane 
• 76-83-5 trityl chloride 
• 271-73-8 1H-Pyrazolo[3,4-b]pyridine 
• 68618-36-0 3-Bromo-1H-pyrazolo<3,4-b>pyridine 
• 36404-90-7 2-fluoropyridine-3-carboxaldehyde 

Downstream Products

• 1383447-03-7 N-((1R,3S)-3-((5-fluoro-2-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide 
• 1422207-26-8 3-(5-(((tert-butyl-dimethylsilyl)oxy)methyl)-6-chloro-3-fluoropyridin-2-yl)-1-trityl-1H-pyrazolo[3,4-b]pyridine 
• 1422207-25-7 2-chloro-5-fluoro-6-(1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)nicotinonitrile 
• 1321925-18-1 6-((3S)-3-(1-amino-2-methylpropyl)pyrrolidin-1-yl)-5-fluoro-2-(1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)nicotinonitrile 
• 1319591-21-3 (R)-tert-butyl 4-(5-cyano-3-fluoro-6-(1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)-2-isobutylpiperazine-1-carboxylate 

Relevant articles and documents

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases

Protein kinase C θ (PKCθ) has a central role in T cell activation and survival; however, the dependency of T cell responses to the inhibition of this enzyme appears to be dictated by the nature of the antigen and by the inflammatory environment. Studies in PKCθ-deficient mice have demonstrated that while antiviral responses are PKCθ-independent, T cell responses associated with autoimmune diseases are PKCθ-dependent. Thus, potent and selective inhibition of PKCθ is expected to block autoimmune T cell responses without compromising antiviral immunity. Herein, we describe the development of potent and selective PKCθ inhibitors, which show exceptional potency in cells and in vivo. By use of a structure based rational design approach, a 1000-fold improvement in potency and 76-fold improvement in selectivity over closely related PKC isoforms such as PKCδ were obtained from the initial HTS hit, together with a big improvement in lipophilic efficiency (LiPE).